A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of squamous cell carcinoma of head and neck (SCCHN) * Recurrent or metastatic SCCHN, not amenable to local therapy * At least 6 months since completion of systemic therapy (chemotherapy or biological anticancer therapy) * No more than 1 prior systemic therapy, given as part of multimodal treatment for locally advanced disease; * No prior systemic therapy for metastatic disease * Radiation therapy must be completed at least 4 weeks before study enrollment. * For palliative therapy, prior radiation therapy allowed to \<25% of the bone marrow (Cristy and Eckerman 1987), and prior radiation to the whole pelvis is not allowed. * Surgery (excluding prior diagnostic biopsy) must be completed at least 4 weeks before study enrollment. * An estimated life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Oken et al. 1982). * Biological tissue available for biomarker analysis on tumor tissue. * Disease status may be measurable or nonmeasurable as defined by Response Evaluation Criteria in Solid Tumors * Patient compliance and geographic proximity that allow for adequate follow-up. * Adequate organ function * Willingness to comply with Contraceptive Regimen * For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen \[for example, intrauterine device (IUD), birth control pills, or barrier device\] during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period. Exclusion Criteria: * Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer. * Previously received treatment with monoclonal antibody therapy, or other signal transduction inhibitors of Epidermal Growth Factor Receptor therapy. * Are receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer. * Serious concomitant systemic disorder (for example, active infection) or psychiatric disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study. * Have serious cardiac disease, such as symptomatic , unstable angina, or the history of myocardial infarction in the previous 12 months. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Have had another primary malignancy other than Head and Neck cancer, unless that prior malignancy was treated at least 2 years previously with no evidence of recurrence. Exception: Patients with a history of in situ carcinoma of the cervix, nonmelanoma skin cancer, or low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed and treated less than 2 years previously. * Presence of clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry. * Have peripheral neuropathy * Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients. * Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). * Unable or unwilling to take folic acid, vitamin B12, or prophylactic corticosteroids. * Recent (within 30 days before enrollment) or concurrent yellow fever vaccination. * Pregnant or breast-feeding